Next Article in Journal
Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival
Previous Article in Journal
White Matter Interstitial Neurons in the Adult Human Brain: 3% of Cortical Neurons in Quest for Recognition
Previous Article in Special Issue
Generation of Functional Vascular Endothelial Cells and Pericytes from Keratinocyte Derived Human Induced Pluripotent Stem Cells
Open AccessReview

Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?

1
Beta Cell Neogenesis (BENE) Research Group, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium
2
ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, 1070 Brussels, Belgium
3
Department of Endocrinology, University Hospital Brussels, 1090 Brussels, Belgium
4
Department of Endocrinology, ASZ Aalst, 9300 Aalst, Belgium
5
Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium
6
Service of Pediatric Endocrinology, Department of Pediatrics, KidZ Health Castle, Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2021, 10(1), 191; https://doi.org/10.3390/cells10010191
Received: 30 November 2020 / Accepted: 12 January 2021 / Published: 19 January 2021
(This article belongs to the Special Issue Pluripotent Stem Cells for Regenerative Medicine)
Diabetes mellitus is a pandemic metabolic disorder that results from either the autoimmune destruction or the dysfunction of insulin-producing pancreatic beta cells. A promising cure is beta cell replacement through the transplantation of islets of Langerhans. However, donor shortage hinders the widespread implementation of this therapy. Human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells, represent an attractive alternative beta cell source for transplantation. Although major advances over the past two decades have led to the generation of stem cell-derived beta-like cells that share many features with genuine beta cells, producing fully mature beta cells remains challenging. Here, we review the current status of beta cell differentiation protocols and highlight specific challenges that are associated with producing mature beta cells. We address the challenges and opportunities that are offered by monogenic forms of diabetes. Finally, we discuss the remaining hurdles for clinical application of stem cell-derived beta cells and the status of ongoing clinical trials. View Full-Text
Keywords: beta cells; cell therapy; stem cells beta cells; cell therapy; stem cells
Show Figures

Figure 1

MDPI and ACS Style

Bourgeois, S.; Sawatani, T.; Van Mulders, A.; De Leu, N.; Heremans, Y.; Heimberg, H.; Cnop, M.; Staels, W. Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet? Cells 2021, 10, 191. https://doi.org/10.3390/cells10010191

AMA Style

Bourgeois S, Sawatani T, Van Mulders A, De Leu N, Heremans Y, Heimberg H, Cnop M, Staels W. Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet? Cells. 2021; 10(1):191. https://doi.org/10.3390/cells10010191

Chicago/Turabian Style

Bourgeois, Stephanie; Sawatani, Toshiaki; Van Mulders, Annelore; De Leu, Nico; Heremans, Yves; Heimberg, Harry; Cnop, Miriam; Staels, Willem. 2021. "Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?" Cells 10, no. 1: 191. https://doi.org/10.3390/cells10010191

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop